General prostate cancer survival time

The survival period of prostate cancer patients is usually 5-10 years. The actual survival time is closely related to factors such as tumor stage, Gleason score, treatment plan, patient age and underlying diseases.

1. Tumor staging:

For early stage localized prostate cancer in stages T1-T2, with radical surgery or radiotherapy, the 10-year survival rate can reach over 95%. The 5-year survival rate for patients with locally advanced T3 stage is about 70%-80%, while the median survival time for metastatic T4 stage prostate cancer is usually 3-5 years. The earlier the stage, the better the prognosis.

2. Gleason score:

Pathological grade is an important prognostic indicator. A score of ≤6 is in the low-risk group, 7 is in the intermediate-risk group, and ≥8 is in the high-risk group. The 10-year specific survival rate in the low-risk group exceeds 98%, and drops to about 60% in the high-risk group. Tumor cells with high scores are poorly differentiated and more likely to metastasize.

3. Treatment plan:

Radical prostatectomy is suitable for patients with limited-stage disease whose life expectancy is >10 years. Radiation therapy can be combined with endocrine therapy for locally advanced cases. Metastatic patients are mainly treated with androgen deprivation, and new endocrine drugs such as abiraterone and enzalutamide can prolong survival.

4. Age factor:

Patients under the age of 70 are more likely to receive radical treatment, while those over the age of 80 are more likely to choose conservative options. Elderly patients with underlying diseases such as cardiovascular disease and diabetes may have their survival time shortened by 20%-30%. For every 10 years of age, the risk of death increases approximately 1.5 times.

5. PSA level:

The 5-year survival rate of those with PSA <10ng/ml at diagnosis exceeds 99%, and drops to 70% when it is >20ng/ml. A PSA doubling time of less than 3 months during treatment indicates a poor prognosis, and the median survival of these patients is usually less than 3 years. Continuous monitoring of PSA changes helps evaluate treatment efficacy.

It is recommended that prostate cancer patients maintain a low-fat and high-fiber diet and supplement vitamin D and selenium in an appropriate amount. Aim for 150 minutes of moderate-intensity exercise every week, such as brisk walking and swimming, and avoid sitting for long periods of time. Regularly review PSA and imaging examinations, pay attention to bone health management during treatment, and seek medical advice promptly if symptoms such as bone pain and difficulty urinating occur. Psychological support is equally important. You can join patient support groups to relieve anxiety.